| Ytd | -72.10% | |
| 1y | -23.02% |
| Open | 2.14 | Prev Close | 2.17 | Low | 2.14 | High | 2.27 | Mkt Cap | 18.47M |
| Vol | 27.53K | Avg Vol | 62.19K | EPS | -1.85 | P/E | N/A | Forward P/E | -3.87 |
| Beta | 1.19 | Short Ratio | 2.80 | Inst. Own | 9.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 2.23 | 200-d Avg | 4.52 | 1yr Est | 21.50 |
LPCN News
SALT LAKE CITY, Aug. 4, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutica
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.32) per share which beat the analyst consens
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary
Live webinar to take place on Friday, June 12, 2026 at 11:00 AM Eastern Time SALT LAKE CITY, June 4,
Oral Presentation detailsTitle:Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpart
SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical compa
BASEL, Switzerland, May 19, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pio
SALT LAKE CITY, May 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical compa
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.54) per share which missed the analyst conse
Lipocine (LPCN) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimat
SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical compan
Mangoceuticals (NASDAQ: MGRX - Get Free Report) and Lipocine (NASDAQ: LPCN - Get Free Report) are bo
Lipocine Inc. (NASDAQ: LPCN - Get Free Report) Director John Higuchi acquired 40,000 shares of the c
Lipocine Inc. (NASDAQ: LPCN - Get Free Report) CEO Mahesh Patel bought 25,000 shares of the company'
BofA downgrades Carvana (CVNA) to Neutral, cutting the price target to $360. Explore the latest anal
On Thursday, the company said LPCN 1154 did not meet its primary endpoint in a Phase 3 trial for pos
Lipocine stock rebounds after a steep drop as LPCN 1154 misses the Phase 3 endpoint, with encouragin
Wall Street analysts changed their outlook on top names. Check out the ratings page for complete cha
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims
US stocks fall, Dow drops over 50 points, real estate shares rise, Acuity Inc. shares decline, Sky Q
Lipocine said LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17
Lipocine Inc. shares are trading lower Thursday after reporting topline safety and efficacy results
US stocks traded lower on Thursday, with the Nasdaq falling 1%. Energy shares rose, while consumer d
In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically
In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically
SALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical com
Lipocine (LPCN) saw its shares surge in the last session with trading volume being higher than avera
SALT LAKE CITY, Feb. 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical comp
HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and raises th
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology plat
SALT LAKE CITY, Jan. 20, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical comp
VANCOUVER, British Columbia, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider. com News Commentary -
Company on track to report topline results early in the second quarter of 2026Second planned Data an
https://ppubs.uspto.gov/api/pdf/downloadPdf/12502396?requestToken=eyJzdWIiOiJiNGI3ZTk4MS0wOTJiLTQyZj
Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026Topline result
Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, st
HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and lowers th
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.59) per share which missed the analyst conse
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintain
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.41) per share which missed the analyst conse
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintain
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintain
New Drug Submission filed by Lipocine's licensing partner Verity PharmaOver 700,000 total prescr
New Drug Submission filed by Lipocine's licensing partner Verity PharmaOver 700,000 total prescr
HC Wainwright & Co. analyst Yi Chen assumes Lipocine (NASDAQ:LPCN) with a Buy rating and anno
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.35) per share which beat the analyst consens